I am not contending Novartis' authority or expertise in the field. Cato made the claim that otat would be a disaster because Novartis left. Otat still looks good, so this was complete bs. He's now just repackaging Novartis leaving into something different but even more lofty (albeit the exact same reasoning) and I am proposing a) has this not already been priced in and b) are there really more negative Ann's to come or more positive announcements to come?
MSB 2022 - The road to commercialisation, page-23
-
- There are more pages in this discussion • 1,506 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
-0.010(1.01%) |
Mkt cap ! $1.118B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 98.0¢ | $4.720M | 4.751M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 171759 | 98.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.0¢ | 16000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |